Startseite Kongressberichte & Archiv 24th Congress of EHA Indolent and mantle-cell non-Hodgkin Lymphoma - clinical

Indolent and mantle-cell non-Hodgkin lymphoma - clinical

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Conclusion: Vemurafenib plus rituximab is a brief, safe and non-myelotoxic regimen that induces MRD-negative durable responses in the majority of relapsed/refractory HCL patients. Randomized testing of this regimen against the chemotherapy-based standard of care in the frontline setting is warranted.

 

S Legouill, Asma Beldi-Ferchiou, VictoriaCacheux, Marion Alcantara, et al.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Conclusion: The Lyma-101 trial successfully achieved its primary endpoint (84.9% of MRD BM negativity after induction) and demonstrates the high efficacy of O-DHAP as induction chemotherapy regimen with an unprecedented high level of MRD negativity. Longer FU is needed to evaluate patient outcome after O-DHAP/ASCT/Obinutuzumab on-demand maintenance. However, both PFS and OS are highly encouraging at one year. 

 

Pau Abrisqueta, Brad Kahl, Lalita Banerjee, Andrew McMillan, et al.

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

Conclusion: The safety profile of Pola-G-Len is consistent with known profiles of the individual drugs. Response rates at EOI with Pola-G-Len are promising, with high CR compared with available R/R FL treatment.

 

Christopher Bolen, Wolfgang Hiddemann, Robert Marcus, Michael Herold, et al.

TREATMENT-DEPENDENCE OF HIGH-RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA

Conclusion: We identified a significant chemotherapy-dependent interaction for two high-risk signatures in de novo FL. These data suggest that high-risk biology may react differently to different chemotherapy backbones, highlighting the challenges of building high-risk signatures for pts independent of treatment.

 

Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo Michele Carella, et al.

EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: RESULTS OF THE PHASE III MABCUTE STUDY

Conclusion: MabCute was unable to fully address the primary study endpoint of PFSrand due to the limited number of events observed. The safety profile of R-SC during prolonged maintenance was consistent with the known profile of R-SC.

 

POSTER

Franck Morschhauser, Pierre Feugier, Ian W Flinn, Robin Gasiorowski, et al.

IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY

Conclusion: Addition of Ven to R-CHOP in 1L DLBCL resulted in improved efficacy in BCL2 IHC+ pts compared with matched GOYA controls. A higher rate of cytopenia, FN and infections was observed in CAVALLI vs GOYA; however, there was no increase in risk of death, and the RDI of chemotherapy was maintained at similar levels.

 

Xiaoqin Yang, François Laliberté, Guillaume Germain, Monika Raut, et al. 

REAL-WORLD TREATMENT PATTERNS OF PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US)

Conclusion: This real-world study of DLBCL patients suggests that a substantial proportion of these patients require treatment beyond 1L, highlighting the unmet need within this population.